Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Mar Drugs ; 22(3)2024 Feb 29.
Article in English | MEDLINE | ID: mdl-38535458

ABSTRACT

The venom of cone snails has been proven to be a rich source of bioactive peptides that target a variety of ion channels and receptors. α-Conotoxins (αCtx) interact with nicotinic acetylcholine receptors (nAChRs) and are powerful tools for investigating the structure and function of the various nAChR subtypes. By studying how conotoxins interact with nAChRs, we can improve our understanding of these receptors, leading to new insights into neurological diseases associated with nAChRs. Here, we describe the discovery and characterization of a novel conotoxin from Conus ateralbus, αCtx-AtIA, which has an amino acid sequence homologous to the well-described αCtx-PeIA, but with a different selectivity profile towards nAChRs. We tested the synthetic αCtx-AtIA using the calcium imaging-based Constellation Pharmacology assay on mouse DRG neurons and found that αCtx-AtIA significantly inhibited ACh-induced calcium influx in the presence of an α7 positive allosteric modulator, PNU-120596 (PNU). However, αCtx-AtIA did not display any activity in the absence of PNU. These findings were further validated using two-electrode voltage clamp electrophysiology performed on oocytes overexpressing mouse α3ß4, α6/α3ß4 and α7 nAChRs subtypes. We observed that αCtx-AtIA displayed no or low potency in blocking α3ß4 and α6/α3ß4 receptors, respectively, but improved potency and selectivity to block α7 nAChRs when compared with αCtx-PeIA. Through the synthesis of two additional analogs of αCtx-AtIA and subsequent characterization using Constellation Pharmacology, we were able to identify residue Trp18 as a major contributor to the activity of the peptide.


Subject(s)
Conotoxins , Conus Snail , Receptors, Nicotinic , Animals , Mice , Calcium , Amino Acid Sequence , alpha7 Nicotinic Acetylcholine Receptor
2.
ACS Chem Neurosci ; 12(14): 2693-2704, 2021 07 21.
Article in English | MEDLINE | ID: mdl-34213884

ABSTRACT

In our efforts to discover new drugs to treat pain, we identified molleamines A-E (1-5) as major neuroactive components of the sea slug, Pleurobranchus forskalii, and their prey, Didemnum molle, tunicates. The chemical structures of molleamines were elucidated by spectroscopy and confirmed by the total synthesis of molleamines A (1) and C (3). Synthetic 3 completely blocked acetylcholine-induced calcium flux in peptidergic nociceptors (PNs) in the somatosensory nervous system. Compound 3 affected neither the α7 nAChR nor the muscarinic acetylcholine receptors in calcium flux assays. In addition to nociceptors, 3 partially blocked the acetylcholine-induced calcium flux in the sympathetic nervous system, including neurons from the superior cervical ganglion. Electrophysiology revealed a block of α3ß4 (mouse) and α6/α3ß4 (rat) nicotinic acetylcholine receptors (nAChRs), with IC50 values of 1.4 and 3.1 µM, respectively. Molleamine C (3) is a partial antagonist, reaching a maximum block of 76-82% of the acetylcholine signal and showing no partial agonist response. Molleamine C (3) may thus provide a lead compound for the development of neuroactive compounds with unique biological properties.


Subject(s)
Receptors, Nicotinic , Urochordata , Animals , Aplysia , Mice , Nicotinic Antagonists/pharmacology , Nylons , Rats , alpha7 Nicotinic Acetylcholine Receptor
3.
J Med Chem ; 64(13): 9513-9524, 2021 07 08.
Article in English | MEDLINE | ID: mdl-34161094

ABSTRACT

α9-Containing nicotinic acetylcholine receptors (nAChRs) are key targets for the treatment of neuropathic pain. α-Conotoxin RgIA4 is a peptide antagonist of human α9α10 nAChRs with high selectivity. However, structural rearrangement reveals a potential liability for clinical applications. We herein report our designer RgIA analogues stabilized by methylene thioacetal as nonopioid analgesic agents. We demonstrate that replacing disulfide loop I [CysI-CysIII] with methylene thioacetal in the RgIA skeleton results in activity loss, whereas substitution of loop II [CysII-CysIV] can be accommodated. The lead molecule, RgIA-5524, exhibits highly selective inhibition of α9α10 nAChRs with an IC50 of 0.9 nM and much reduced degradation in human serum. In vivo studies showed that RgIA-5524 relieves chemotherapy-induced neuropathic pain in wild type but not α9 knockout mouse models, demonstrating that α9-containing nAChRs are necessary for the therapeutic effects. This work highlights the application of methylene thioacetal as a disulfide surrogate in conotoxin-based, disulfide-rich peptide drugs.


Subject(s)
Acetals/pharmacology , Conotoxins/pharmacology , Neuralgia/drug therapy , Receptors, Nicotinic/metabolism , Sulfhydryl Compounds/pharmacology , Acetals/chemistry , Conotoxins/chemistry , Dose-Response Relationship, Drug , Drug Discovery , Humans , Molecular Structure , Neuralgia/metabolism , Structure-Activity Relationship , Sulfhydryl Compounds/chemistry
4.
J Med Chem ; 64(13): 9271-9278, 2021 07 08.
Article in English | MEDLINE | ID: mdl-34142837

ABSTRACT

Venom-derived compounds are of broad interest in neuropharmacology and drug development. α-Conotoxins are small disulfide-containing peptides from Conus snails that target nicotinic acetylcholine receptors (nAChRs) and are in clinical development for non-opioid-based treatment of intractable pain. Although refined by evolution for interaction with target prey receptors, enhancements of pharmacological properties are needed for use in mammalian systems. Therefore, we synthesized analogues of α-conotoxin RgIA using a combination of selective penicillamine substitutions together with natural and non-natural amino acid replacements. This approach resulted in a peptide with 9000-fold increased potency on the human α9α10 nAChR and improved resistance to disulfide shuffling compared to the native peptide. The lead analogue, RgIA-5474, potently blocked α9α10 nAChRs, but not opioid- or other pain-related targets. In addition, RgIA-5474 effectively reversed chemotherapy-induced neuropathic pain.


Subject(s)
Analgesics/pharmacology , Conotoxins/pharmacology , Drug Development , Neuralgia/drug therapy , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/metabolism , Analgesics/chemical synthesis , Analgesics/chemistry , Conotoxins/chemical synthesis , Conotoxins/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Neuralgia/metabolism , Nicotinic Antagonists/chemical synthesis , Nicotinic Antagonists/chemistry , Structure-Activity Relationship
5.
J Med Chem ; 63(15): 8380-8387, 2020 08 13.
Article in English | MEDLINE | ID: mdl-32597184

ABSTRACT

Non-opioid therapeutics for the treatment of neuropathic pain are urgently needed to address the ongoing opioid crisis. Peptides from cone snail venoms have served as invaluable molecules to target key pain-related receptors but can suffer from unfavorable physicochemical properties, which limit their therapeutic potential. In this work, we developed conformationally constrained α-RgIA analogues with high potency, receptor selectivity, and enhanced human serum stability to target the human α9α10 nicotinic acetylcholine receptor. The key lactam linkage introduced in α-RgIA fixed the favored globular conformation and suppressed disulfide scrambling. The NMR structure of the macrocyclic peptide overlays well with that of α-RgIA4, demonstrating that the cyclization does not perturb the overall conformation of backbone and key side-chain residues. Finally, a molecular docking model was used to rationalize the selective binding between a macrocyclic analogue and the α9α10 nicotinic acetylcholine receptor. These conformationally constrained antagonists are therefore promising candidates for antinociceptive therapeutic intervention.


Subject(s)
Conotoxins/chemistry , Conotoxins/pharmacology , Nicotinic Antagonists/chemistry , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/metabolism , Animals , Conus Snail/chemistry , Drug Design , Humans , Macrocyclic Compounds/chemistry , Macrocyclic Compounds/pharmacology , Molecular Conformation , Molecular Docking Simulation , Peptides, Cyclic/chemistry , Peptides, Cyclic/pharmacology , Protein Subunits/metabolism , Xenopus laevis
6.
J Med Chem ; 61(23): 10531-10544, 2018 12 13.
Article in English | MEDLINE | ID: mdl-30403486

ABSTRACT

Adenocarcinoma and glioblastoma cell lines express α7- and α9α10-containing nicotinic acetylcholine receptors (nAChRs), whose activation promotes tumor cell growth. On these cells, the triethylammoniumethyl ether of 4-stilbenol MG624, a known selective antagonist of α7 and α9α10 nAChRs, has antiproliferative activity. The structural analogy of MG624 with the mitocan RDM-4'BTPI, triphenylphosphoniumbutyl ether of pterostilbene, suggested us that molecular hybridization among their three substructures (stilbenoxy residue, alkylene linker, and terminal onium) and elongation of the alkylene linker might result in novel antitumor agents with higher potency and selectivity. We found that lengthening the ethylene bridge in the triethylammonium derivatives results in more potent and selective toxicity toward adenocarcinoma and glioblastoma cells, which was paralleled by increased α7 and α9α10 nAChR antagonism and improved ability of reducing mitochondrial ATP production. Elongation of the alkylene linker was advantageous also for the triphenylphosphonium derivatives resulting in a generalized enhancement of antitumor activity, associated with increased mitotoxicity.


Subject(s)
Glioblastoma/pathology , Reactive Oxygen Species/chemistry , Receptors, Nicotinic/metabolism , Stilbenes/chemistry , Stilbenes/pharmacology , alpha7 Nicotinic Acetylcholine Receptor/antagonists & inhibitors , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Humans
7.
Br J Pharmacol ; 175(11): 1957-1972, 2018 06.
Article in English | MEDLINE | ID: mdl-28726253

ABSTRACT

BACKGROUND AND PURPOSE: Tobacco smoke contains many classes of carcinogens and although nicotine is unable to initiate tumourigenesis in humans and rodents, it promotes tumour growth and metastasis in lung tumours by acting on neuronal nicotinic ACh receptors (nAChRs). The aim of this study was to identify molecularly, biochemically and pharmacologically which nAChR subtypes are expressed and functionally activated by nicotine in lung cancer cell lines. EXPERIMENTAL APPROACH: We used A549 and H1975 adenocarcinoma cell lines derived from lung tumours to test the in vitro effects of nicotine, and nAChR subtype-specific peptides and compounds. KEY RESULTS: The two adenocarcinoma cell lines express distinctive nAChR subtypes, and this affects their nicotine-induced proliferation. In A549 cells, nAChRs containing the α7 or α9 subunits not only regulate nicotine-induced cell proliferation but also the activation of the Akt and ERK pathways. Blocking these nAChRs by means of subtype-specific peptides, or silencing their expression by means of subunit-specific siRNAs, abolishes nicotine-induced proliferation and signalling. Moreover, we found that the α7 antagonist MG624 also acts on α9-α10 nAChRs, blocks the effects of nicotine on A549 cells and has dose-dependent cytotoxic activity. CONCLUSIONS AND IMPLICATIONS: These results highlight the pathophysiological role of α7- and α9-containing receptors in promoting non-small cell lung carcinoma cell growth and intracellular signalling and provide a framework for the development of new drugs that specifically target the receptors expressed in lung tumours. LINKED ARTICLES: This article is part of a themed section on Nicotinic Acetylcholine Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.11/issuetoc.


Subject(s)
Adenocarcinoma/drug therapy , Lung Neoplasms/drug therapy , Nicotine/pharmacology , Receptors, Nicotinic/metabolism , alpha7 Nicotinic Acetylcholine Receptor/antagonists & inhibitors , A549 Cells , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Quaternary Ammonium Compounds/pharmacology , Stilbenes/pharmacology , Structure-Activity Relationship , alpha7 Nicotinic Acetylcholine Receptor/metabolism
8.
Proc Natl Acad Sci U S A ; 112(30): E4026-35, 2015 Jul 28.
Article in English | MEDLINE | ID: mdl-26170295

ABSTRACT

We identified a previously unidentified conotoxin gene from Conus generalis whose precursor signal sequence has high similarity to the O1-gene conotoxin superfamily. The predicted mature peptide, αO-conotoxin GeXIVA (GeXIVA), has four Cys residues, and its three disulfide isomers were synthesized. Previously pharmacologically characterized O1-superfamily peptides, exemplified by the US Food and Drug Administration-approved pain medication, ziconotide, contain six Cys residues and are calcium, sodium, or potassium channel antagonists. However, GeXIVA did not inhibit calcium channels but antagonized nicotinic AChRs (nAChRs), most potently on the α9α10 nAChR subtype (IC50 = 4.6 nM). Toxin blockade was voltage-dependent, and kinetic analysis of toxin dissociation indicated that the binding site of GeXIVA does not overlap with the binding site of the competitive antagonist α-conotoxin RgIA. Surprisingly, the most active disulfide isomer of GeXIVA is the bead isomer, comprising, according to NMR analysis, two well-resolved but uncoupled disulfide-restrained loops. The ribbon isomer is almost as potent but has a more rigid structure built around a short 310-helix. In contrast to most α-conotoxins, the globular isomer is the least potent and has a flexible, multiconformational nature. GeXIVA reduced mechanical hyperalgesia in the rat chronic constriction injury model of neuropathic pain but had no effect on motor performance, warranting its further investigation as a possible therapeutic agent.


Subject(s)
Conotoxins/chemistry , Conus Snail/chemistry , Nicotinic Antagonists/chemistry , Receptors, Nicotinic/chemistry , Amides/chemistry , Amino Acid Sequence , Animals , Binding Sites , Calcium Channels/chemistry , Cloning, Molecular , Endoplasmic Reticulum/metabolism , Hyperalgesia/drug therapy , Inhibitory Concentration 50 , Male , Models, Molecular , Molecular Sequence Data , Neuralgia/therapy , Oocytes/cytology , Protein Conformation , Protein Sorting Signals , Rats , Rats, Sprague-Dawley , Xenopus laevis
9.
J Med Chem ; 57(8): 3511-21, 2014 Apr 24.
Article in English | MEDLINE | ID: mdl-24649848

ABSTRACT

α-Conotoxins are disulfide-rich peptide neurotoxins that selectively inhibit neuronal nicotinic acetylcholine receptors (nAChRs). The α3ß4 nAChR subtype has been identified as a novel target for managing nicotine addiction. Using a mixture-based positional-scanning synthetic combinatorial library (PS-SCL) with the α4/4-conotoxin BuIA framework, we discovered a highly potent and selective α3ß4 nAChR antagonist. The initial PS-SCL consisted of a total of 113 379 904 sequences that were screened for α3ß4 nAChR inhibition, which facilitated the design and synthesis of a second generation library of 64 individual α-conotoxin derivatives. Eleven analogues were identified as α3ß4 nAChR antagonists, with TP-2212-59 exhibiting the most potent antagonistic activity and selectivity over the α3ß2 and α4ß2 nAChR subtypes. Final electrophysiological characterization demonstrated that TP-2212-59 inhibited acetylcholine evoked currents in α3ß4 nAChRs heterogeneously expressed in Xenopus laevis oocytes with a calculated IC50 of 2.3 nM and exhibited more than 1000-fold selectivity over the α3ß2 and α7 nAChR subtypes. As such, TP-2212-59 is among the most potent α3ß4 nAChRs antagonists identified to date and further demonstrates the utility of mixture-based combinatorial libraries in the discovery of novel α-conotoxin derivatives with refined pharmacological activity.


Subject(s)
Combinatorial Chemistry Techniques/methods , Conotoxins/pharmacology , Nicotinic Antagonists/chemical synthesis , Receptors, Nicotinic/drug effects , Drug Discovery , Drug Evaluation, Preclinical , HEK293 Cells , Humans , Membrane Potentials/drug effects , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/chemistry , Structure-Activity Relationship
10.
Eur J Pharmacol ; 670(2-3): 500-8, 2011 Nov 30.
Article in English | MEDLINE | ID: mdl-21944926

ABSTRACT

Chronic pain is inadequately managed with currently available classes of analgesic drugs. Recently, peptide antagonists of the α9α10 nicotinic acetylcholine receptor were shown to be analgesic. The present study was conducted to characterize a novel small molecule, non-peptide antagonist at nicotinic receptors. The tetrakis-quaternary ammonium compound ZZ-204G was evaluated for functional activity on cloned nicotinic receptors expressed in Xenopus oocytes. In-vivo efficacy was assessed in rat models of tonic inflammatory pain (formalin test), neuropathic pain (chronic constriction nerve injury), and thermal nociception (tail flick test). ZZ-204G was an antagonist at nicotinic receptors inhibiting the α9α10 subtype with an IC50 of 0.51 (0.35-0.72) nM. Antagonist activity at other nicotinic subtypes (α1ß1δε, α2ß2, α2ß4, α3ß2, α3ß4, α4ß2, α4ß4, α6/α3ß2ß3, α6/α3ß4 and α7) was 10-1000-fold lower than at the α9α10 subtype. In competition binding assays, the k(i) of ZZ-204G at γ-aminobutyric acid(A), serotonin(3), γ-aminobutyric acid(B), κ- and µ-opioid receptors was 1000- to >10,000-fold lower than at α9α10 nicotinic receptors. Parenteral administration of ZZ-204G dose-dependently decreased nociceptive behaviors (paw flinches) in the formalin test and mechanical hyperalgesia in the chronic constriction nerve injury model of neuropathic pain. ZZ-204G was not antinociceptive in the tail flick assay. Results from the rotarod assay indicated that lower doses of ZZ-204G that were analgesic did not alter motor function. In summary, ZZ-204G represents a prototype small molecule antagonist for α9α10 nicotinic receptors and provides a novel molecular scaffold for analgesic agents with the potential to treat chronic inflammatory or neuropathic pain.


Subject(s)
Alkynes/chemistry , Alkynes/pharmacology , Analgesics/chemistry , Analgesics/pharmacology , Benzene/chemistry , Benzene/pharmacology , Nicotinic Antagonists/chemistry , Nicotinic Antagonists/pharmacology , Pyridinium Compounds/chemistry , Pyridinium Compounds/pharmacology , Receptors, Nicotinic/metabolism , Alkynes/therapeutic use , Analgesics/therapeutic use , Animals , Behavior, Animal/drug effects , Benzene/therapeutic use , Constriction, Pathologic/complications , Feasibility Studies , Formaldehyde/adverse effects , Hyperalgesia/drug therapy , Hyperalgesia/etiology , Hyperalgesia/physiopathology , Motor Activity/drug effects , Neuralgia/chemically induced , Neuralgia/drug therapy , Neuralgia/physiopathology , Nicotinic Antagonists/therapeutic use , Protein Subunits/antagonists & inhibitors , Pyridinium Compounds/therapeutic use , Rats
11.
Bioorg Med Chem Lett ; 21(8): 2476-9, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21397497

ABSTRACT

A series of azaaromatic quaternary ammonium analogs has been discovered as potent and selective α9α10 nicotinic acetylcholine receptor (nAChR) antagonists. The preliminary structure-activity relationships of these analogs suggest that increased rigidity in the linker units results in higher potency in inhibition of α9α10 nAChRs and greater selectivity over α7 nAChRs. These analogs represent a new class of analgesic for the treatment of neuropathic and tonic inflammatory pain.


Subject(s)
Analgesics/chemistry , Nicotinic Antagonists/chemistry , Pain/drug therapy , Receptors, Nicotinic/chemistry , Analgesics/chemical synthesis , Analgesics/therapeutic use , Animals , Drug Evaluation, Preclinical , Nicotinic Antagonists/chemical synthesis , Nicotinic Antagonists/therapeutic use , Quaternary Ammonium Compounds/chemical synthesis , Quaternary Ammonium Compounds/chemistry , Quaternary Ammonium Compounds/therapeutic use , Rats , Receptors, Nicotinic/metabolism , Structure-Activity Relationship
12.
FASEB J ; 24(12): 5113-23, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20739611

ABSTRACT

α6* (asterisk indicates the presence of additional subunits) nicotinic acetylcholine receptors (nAChRs) are broadly implicated in catecholamine-dependent disorders that involve attention, motor movement, and nicotine self-administration. Different molecular forms of α6 nAChRs mediate catecholamine release, but receptor differentiation is greatly hampered by a paucity of subtype selective ligands. α-Conotoxins are nAChR-targeted peptides used by Conus species to incapacitate prey. We hypothesized that distinct conotoxin-binding kinetics could be exploited to develop a series of selective probes to enable study of native receptor subtypes. Proline6 of α-conotoxin BuIA was found to be critical for nAChR selectivity; substitution of proline6 with 4-hydroyxproline increased the IC(50) by 2800-fold at α6/α3ß2ß3 but only by 6-fold at α6/α3ß4 nAChRs (to 1300 and 12 nM, respectively). We used conotoxin probes together with subunit-null mice to interrogate nAChR subtypes that modulate hippocampal norepinephrine release. Release was abolished in α6-null mutant mice. α-Conotoxin BuIA[T5A;P6O] partially blocked norepinephrine release in wild-type controls but failed to block release in ß4(-/-) mice. In contrast, BuIA[T5A;P6O] failed to block dopamine release in the wild-type striatum known to contain α6ß2* nAChRs. BuIA[T5A;P6O] is a novel ligand for distinguishing between closely related α6* nAChRs; α6ß4* nAChRs modulate norepinephrine release in hippocampus but not dopamine release in striatum.


Subject(s)
Conotoxins/metabolism , Nicotine/metabolism , Norepinephrine/metabolism , Receptors, Nicotinic/metabolism , Animals , Female , Hydroxylation , Ligands , Male , Mice , Mice, Inbred C57BL , Oocytes/metabolism , Proline/metabolism , Xenopus
13.
J Biol Chem ; 285(16): 12355-66, 2010 Apr 16.
Article in English | MEDLINE | ID: mdl-20145249

ABSTRACT

Different nicotinic acetylcholine receptor (nAChR) subtypes are implicated in learning, pain sensation, and disease states, including Parkinson disease and nicotine addiction. alpha-Conotoxins are among the most selective nAChR ligands. Mechanistic insights into the structure, function, and receptor interaction of alpha-conotoxins may serve as a platform for development of new therapies. Previously characterized alpha-conotoxins have a highly conserved Ser-Xaa-Pro motif that is crucial for potent nAChR interaction. This study characterized the novel alpha-conotoxin LtIA, which lacks this highly conserved motif but potently blocked alpha3beta2 nAChRs with a 9.8 nm IC(50) value. The off-rate of LtIA was rapid relative to Ser-Xaa-Pro-containing alpha-conotoxin MII. Nevertheless, pre-block of alpha3beta2 nAChRs with LtIA prevented the slowly reversible block associated with MII, suggesting overlap in their binding sites. nAChR beta subunit ligand-binding interface mutations were used to examine the >1000-fold selectivity difference of LtIA for alpha3beta2 versus alpha3beta4 nAChRs. Unlike MII, LtIA had a >900-fold increased IC(50) value on alpha3beta2(F119Q) versus wild type nAChRs, whereas T59K and V111I beta2 mutants had little effect. Molecular docking simulations suggested that LtIA had a surprisingly shallow binding site on the alpha3beta2 nAChR that includes beta2 Lys-79. The K79A mutant disrupted LtIA binding but was without effect on an LtIA analog where the Ser-Xaa-Pro motif is present, consistent with distinct binding modes.


Subject(s)
Conotoxins/pharmacology , Receptors, Nicotinic/drug effects , Amino Acid Sequence , Animals , Binding Sites/genetics , Conotoxins/chemistry , Conotoxins/classification , Conotoxins/genetics , Conus Snail/genetics , Female , In Vitro Techniques , Mice , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Nicotinic Antagonists/chemistry , Nicotinic Antagonists/pharmacology , Nuclear Magnetic Resonance, Biomolecular , Oocytes/drug effects , Oocytes/metabolism , Oxidation-Reduction , Protein Folding , Rats , Receptors, Nicotinic/genetics , Receptors, Nicotinic/metabolism , Recombinant Proteins/drug effects , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Structural Homology, Protein , Xenopus
14.
J Pharmacol Exp Ther ; 325(3): 910-9, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18323456

ABSTRACT

The alpha7 nicotinic acetylcholine receptors (nAChRs) are widely expressed both in the central nervous system (CNS) and periphery. In the CNS, 125I-alpha-bungarotoxin is commonly used to identify alpha7 nAChRs specifically. However, alpha-bungarotoxin also interacts potently with alpha1* and alpha9alpha10 nAChRs, two receptor subtypes in peripheral tissues that are colocalized with the alpha7 subtype. [3H]Methyllycaconitine is also frequently used as an alpha7-selective antagonist, but it has significant affinity for alpha6* and alpha9alpha10 nAChR subtypes. In this study, we have developed a highly alpha7-selective alpha-conotoxin radioligand by iodination of a naturally occurring histidine. Both mono- and diiodo derivatives were generated and purified (specific activities were 2200 and 4400 Ci mmol(-1), respectively). The properties of the mono- and diiodo derivatives were very similar to each other, but the diiodo was less stable. For monoidodo peptide, saturation binding to mouse hippocampal membranes demonstrated a K(d) value of 1.15 +/- 0.13 nM, similar to that of 125I-alpha-bungarotoxin in the same preparations (0.52 +/- 0.16 nM). Association and dissociation kinetics were relatively rapid (k(obs) for association at 1 nM was 0.027 +/- 0.007 min(-1); k(off) = 0.020 +/- 0.001 min(-1)). Selectivity was confirmed with autoradiography using alpha7-null mutant tissue: specific binding was abolished in all regions of alpha7(-/-) brains, whereas wild-type mice expressed high levels of labeling and low nonspecific binding. 125I-alpha-conotoxin ArIB[V11L; V16A] should prove useful where alpha7 nAChRs are coexpressed with other subtypes that are also labeled by existing ligands. Furthermore, true equilibrium binding experiments could be performed on alpha7 nAChRs, something that is impossible with 125I-alpha-bungarotoxin.


Subject(s)
Conotoxins/metabolism , Nicotinic Antagonists/metabolism , Peptides/metabolism , Receptors, Nicotinic/metabolism , Animals , Brain/metabolism , Conotoxins/chemical synthesis , Electric Organ/metabolism , Histidine/chemistry , Iodine Radioisotopes , Male , Membranes/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Nicotinic Antagonists/chemical synthesis , Oocytes/metabolism , Peptides/chemical synthesis , Radioligand Assay , Receptors, Nicotinic/genetics , Torpedo , Xenopus , alpha7 Nicotinic Acetylcholine Receptor
15.
Biochemistry ; 46(22): 6628-38, 2007 Jun 05.
Article in English | MEDLINE | ID: mdl-17497892

ABSTRACT

Nicotinic acetylcholine receptors (nAChRs) that contain an alpha7 subunit are widely distributed in neuronal and nonneuronal tissue. These receptors are implicated in the release of neurotransmitters such as glutamate and in functions ranging from thought processing to inflammation. Currently available ligands for alpha7 nAChRs have substantial affinity for one or more other nAChR subtypes, including those with an alpha1, alpha3, alpha6, and/or alpha9 subunit. An alpha-conotoxin gene was cloned from Conus arenatus. Predicted peptides were synthesized and found to potently block alpha3-, alpha6-, and alpha7-containing nAChRs. Structure-activity information regarding conotoxins from distantly related Conus species was employed to modify the C. arenatus derived toxin into a novel, highly selective alpha7 nAChR antagonist. This ligand, alpha-CtxArIB[V11L,V16D], has low nanomolar affinity for rat alpha7 homomers expressed in Xenopus laevis oocytes, and antagonism is slowly reversible. Kinetic analysis provided insight into the mechanism of antagonism. alpha-CtxArIB interacts with five ligand binding sites per alpha7 receptor, and occupation of a single site is sufficient to block function. The peptide was also shown to be highly selective in competition binding assays in rat brain membranes. alpha-CtxArIB[V11L,V16D] is the most selective ligand yet reported for alpha7 nAChRs.


Subject(s)
Conotoxins/chemistry , Conotoxins/chemical synthesis , Nicotinic Antagonists/pharmacology , Receptors, Nicotinic/drug effects , Synaptic Transmission/drug effects , Acetylcholine/metabolism , Animals , Binding Sites/physiology , Brain/metabolism , Cloning, Molecular , Conotoxins/isolation & purification , Conotoxins/pharmacology , Glutamates/metabolism , Kinetics , Models, Biological , Molecular Sequence Data , Nicotinic Antagonists/chemical synthesis , Nicotinic Antagonists/isolation & purification , Oocytes/drug effects , Oocytes/metabolism , Rats , Structure-Activity Relationship , Xenopus laevis , alpha7 Nicotinic Acetylcholine Receptor
16.
J Biol Chem ; 281(34): 24678-86, 2006 Aug 25.
Article in English | MEDLINE | ID: mdl-16803900

ABSTRACT

The molluskan acetylcholine-binding protein (AChBP) is a homolog of the extracellular binding domain of the pentameric ligand-gated ion channel family. AChBP most closely resembles the alpha-subunit of nicotinic acetylcholine receptors and in particular the homomeric alpha7 nicotinic receptor. We report the isolation and characterization of an alpha-conotoxin that has the highest known affinity for the Lymnaea AChBP and also potently blocks the alpha7 nAChR subtype when expressed in Xenopus oocytes. Remarkably, the peptide also has high affinity for the alpha3beta2 nAChR indicating that alpha-conotoxin OmIA in combination with the AChBP may serve as a model system for understanding the binding determinants of alpha3beta2 nAChRs. alpha-Conotoxin OmIA was purified from the venom of Conus omaria. It is a 17-amino-acid, two-disulfide bridge peptide. The ligand is the first alpha-conotoxin with higher affinity for the closely related receptor subtypes, alpha3beta2 versus alpha6beta2, and selectively blocks these two subtypes when compared with alpha2beta2, alpha4beta2, and alpha1beta1deltaepsilon nAChRs.


Subject(s)
Carrier Proteins/metabolism , Conotoxins/metabolism , Receptors, Nicotinic/metabolism , Amino Acid Sequence , Animals , Carrier Proteins/chemistry , Conotoxins/chemistry , Ligands , Lymnaea , Molecular Sequence Data , Protein Binding , Protein Subunits/chemistry , Protein Subunits/metabolism , Receptors, Nicotinic/chemistry , Sequence Alignment , Xenopus , alpha7 Nicotinic Acetylcholine Receptor
17.
J Biol Chem ; 280(1): 80-7, 2005 Jan 07.
Article in English | MEDLINE | ID: mdl-15520009

ABSTRACT

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels. Alpha subunits, together with beta 2 and/or beta 4 subunits, form ligand-binding sites at alpha/beta subunit interfaces. Predatory marine snails of the genus Conus are a rich source of nAChR-targeted peptides. Using conserved features of the alpha-conotoxin signal sequence and 3'-untranslated sequence region, we have cloned a novel gene from the fish-eating snail, Conus bullatus; the gene codes for a previously unreported alpha-conotoxin with unusual 4/4 spacing of amino acids in the two disulfide loops. Chemical synthesis of the predicted mature toxin was performed. The resulting peptide, alpha-conotoxin BuIA, was tested on cloned nAChRs expressed in Xenopus oocytes. The peptide potently blocks numerous rat nAChR subtypes, with highest potency for alpha 3- and chimeric alpha 6-containing nAChRs; BuIA blocks alpha 6/alpha 3 beta 2 nAChRs with a 40,000-fold lower IC(50) than alpha 4 beta 2 nAChRs. The kinetics of toxin unblock are dependent on the beta subunit. nAChRs with a beta 4 subunit have very slow off-times, compared with the corresponding beta 2 subunit-containing nAChR. In each instance, rat alpha x beta 4 may be distinguished from rat alpha x beta 2 by the large difference in time to recover from toxin block. Similar results are obtained when comparing mouse alpha 3 beta 2 to mouse alpha 3 beta 4, and human alpha 3 beta2 to human alpha 3 beta 4, indicating that the beta subunit dependence extends across species. Thus, alpha-conotoxin BuIA also represents a novel probe for distinguishing between beta 2- and beta 4-containing nAChRs.


Subject(s)
Conotoxins/chemistry , Receptors, Nicotinic/drug effects , Snails/chemistry , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , Conotoxins/genetics , Conotoxins/pharmacology , Kinetics , Mice , Molecular Sequence Data , Protein Subunits , Rats , Receptors, Nicotinic/chemistry , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/drug effects , Recombinant Proteins/chemistry , Recombinant Proteins/drug effects , Signal Transduction/drug effects , Species Specificity
18.
Mol Pharmacol ; 65(4): 944-52, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15044624

ABSTRACT

Neuronal nicotinic acetylcholine receptors (nAChRs) both mediate direct cholinergic synaptic transmission and modulate synaptic transmission by other neurotransmitters. Novel ligands are needed as probes to discriminate among structurally related nAChR subtypes. Alpha-conotoxin MII, a selective ligand that discriminates among a variety of nAChR subtypes, fails to discriminate well between some subtypes containing the closely related alpha3 and alpha6 subunits. Structure-function analysis of alpha-conotoxin MII was performed in an attempt to generate analogs with preference for alpha6-containing [alpha6(*) (asterisks indicate the possible presence of additional subunits)] nAChRs. Alanine substitution resulted in several analogs with decreased activity at alpha3(*) versus alpha6(*) nAChRs heterologously expressed in Xenopus laevis oocytes. From the initial analogs, a series of mutations with two alanine substitutions was synthesized. Substitution at His9 and Leu15 (MII[H9A;L15A]) resulted in a 29-fold lower IC(50) at alpha6beta4 versus alpha3beta4 nAChRs. The peptide had a 590-fold lower IC(50) for alpha6/alpha3beta2 versus alpha3beta2 and a 2020-fold lower IC(50) for alpha6/alpha3beta2beta3 versus alpha3beta2 nAChRs. MII[H9A;L15A] had little or no activity at alpha2beta2, alpha2beta4, alpha3beta4, alpha4beta2, alpha4beta4, and alpha7 nAChRs. Functional block by MII[H9A;L15A] of rat alpha6/alpha3beta2beta3 nAChRs (IC(50) = 2.4 nM) correlated well with the inhibition constant of MII[H9A;L15A] for [(125)I]alpha-conotoxin MII binding to putative alpha6beta2(*) nAChRs in mouse brain homogenates (K(i) = 3.3 nM). Thus, structure-function analysis of alpha-conotoxin MII enabled the creation of novel selective antagonists for discriminating among nAChRs containing alpha3 and alpha6 subunits.


Subject(s)
Conotoxins/pharmacology , Protein Subunits/metabolism , Receptors, Nicotinic/metabolism , Animals , Conotoxins/chemistry , Kinetics , Mice , Oocytes/drug effects , Oocytes/metabolism , Peptides/chemistry , Peptides/pharmacology , Rats , Xenopus laevis
19.
J Neurosci ; 23(24): 8445-52, 2003 Sep 17.
Article in English | MEDLINE | ID: mdl-13679412

ABSTRACT

Until now, there have been no antagonists to discriminate between heteromeric nicotinic acetylcholine receptors (nAChRs) containing the very closely related alpha6 and alpha3 subunits. nAChRs containing alpha3, alpha4, or alpha6 subunits in combination with beta2, occasionally beta4, and sometimes beta3 or alpha5 subunits, are thought to play important roles in cognitive function, pain perception, and the reinforcing properties of nicotine. We cloned a novel gene from the predatory marine snail Conus purpurascens. The predicted peptide, alpha-conotoxin PIA, potently blocks the chimeric alpha6/alpha3beta2beta3 subunit combination as expressed in oocytes but neither the muscle nor the major neuronal nAChR alpha4beta2. Additionally, this toxin is the first described ligand to discriminate between nAChRs containing alpha6 and alpha3 subunits. Exploiting the unusual intron conservation of conotoxin genes may represent a more general approach for defining conotoxin ligand scaffolds to discriminate among closely related receptor populations.


Subject(s)
Mollusk Venoms/pharmacology , Receptors, Nicotinic/drug effects , Amino Acid Sequence , Animals , Electrophysiology , Gene Expression , Humans , Kinetics , Molecular Sequence Data , Mollusk Venoms/chemistry , Mollusk Venoms/genetics , Mollusk Venoms/isolation & purification , Oocytes/drug effects , Oocytes/metabolism , Patch-Clamp Techniques , Protein Subunits/drug effects , Protein Subunits/genetics , Protein Subunits/metabolism , Rats , Receptors, Nicotinic/genetics , Receptors, Nicotinic/metabolism , Sequence Homology, Amino Acid , Snails , Substrate Specificity , Transfection , Xenopus
20.
J Biol Chem ; 277(37): 33610-5, 2002 Sep 13.
Article in English | MEDLINE | ID: mdl-12114524

ABSTRACT

Many venomous organisms produce toxins that disrupt neuromuscular communication to paralyze their prey. One common class of such toxins comprises nicotinic acetylcholine receptor antagonists (nAChRs). Thus, most toxins that act on nAChRs are targeted to the neuromuscular subtype. The toxin characterized in this report, alpha-conotoxin GIC, is a most striking exception. The 16-amino acid peptide was identified from a genomic DNA clone from Conus geographus. The predicted mature toxin was synthesized, and synthetic toxin was used in all studies described. alpha-Conotoxin GIC shows no paralytic activity in fish or mice. Furthermore, even at concentrations up to 100 microm, the peptide has no detectable effect on the human muscle nicotinic receptor subtype heterologously expressed in Xenopus oocytes. In contrast, the toxin has high affinity (IC(50) approximately 1.1 nm) for the human alpha3beta2 subunit combination, making it the most neuronally selective nicotinic antagonist characterized thus far. Although alpha-conotoxin GIC shares some sequence similarity with alpha-conotoxin MII, which is also a potent alpha3beta2 nicotinic antagonist, it is much less hydrophobic, and the kinetics of channel block are substantially different. It is noteworthy that the nicotinic ligands in C. geographus venom fit an emerging pattern in venomous predators, with one nicotinic antagonist targeted to the muscle subtype (thereby causing paralysis) and a second nicotinic antagonist targeted to the alpha3beta2 nAChR subtype (possibly inhibiting the fight-or-flight response).


Subject(s)
Conotoxins/pharmacology , Nicotinic Antagonists/pharmacology , Amino Acid Sequence , Animals , Base Sequence , Conotoxins/chemical synthesis , Conotoxins/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Sequence Data , Xenopus
SELECTION OF CITATIONS
SEARCH DETAIL
...